RepliCel Life Sciences Management

Management criteria checks 3/4

RepliCel Life Sciences' CEO is Andrew Schutte, appointed in Nov 2022, has a tenure of 5.92 years. directly owns 26.77% of the company’s shares, worth CA$51.22K. The average tenure of the management team and the board of directors is 2 years and 5.9 years respectively.

Key information

Andrew Schutte

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	2yrs
CEO ownership	26.8%
Management average tenure	2yrs
Board average tenure	5.9yrs

Recent management updates

Recent updates

CEO

Andrew Schutte (34 yo)

2yrs

Tenure

CA$8,917

Compensation

Mr. Andrew Schutte serves as President, Chief Executive Officer & Director of RepliCel Life Sciences Inc. since November 28, 2022. He served as an Independent Director of RepliCel Life Sciences Inc. since...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Andrew Schutte	President	2yrs	CA$8.92k	26.77% CA$ 51.2k
Kevin McElwee	Co-Founder & Chief Scientific Officer	13.3yrs	CA$30.00k	2.04% CA$ 3.9k
Ben Austring	Chief Legal Officer	2yrs	CA$14.50k	0.49% CA$ 942.8
David Kwok	Chief Financial Officer	1.3yrs	no data	no data

2.0yrs

Average Tenure

Experienced Management: RP's management team is considered experienced (2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Andrew Schutte	President	5.9yrs	CA$8.92k	26.77% CA$ 51.2k
David Hall	Independent Chairman of the Board	13.9yrs	CA$17.75k	1.35% CA$ 2.6k
Jean Krutmann	Member of Clinical Advisory Board	no data	no data	no data
Ross Davidson	Chairman of Clinical Advisory Board	11.1yrs	no data	no data
Peter Lewis	Independent Director	13.5yrs	CA$14.45k	0.96% CA$ 1.8k
R. Buckler	Director	8.8yrs	CA$240.85k	0.010% CA$ 20.0
Gary Boddington	Independent Director	3.4yrs	CA$16.25k	0.48% CA$ 926.1
Jamie MacKay	Director	1.3yrs	no data	15.44% CA$ 29.5k
Tsukasa Kumai	Member of Clinical Advisory Board	no data	no data	no data
Akimichi Morita	Member of Clinical Advisory Board	3.5yrs	no data	no data
Kunihiko Suzuki	Senior Strategic Advisor to Directors	3.1yrs	no data	no data

5.9yrs

Average Tenure

61.5yo

Average Age

Experienced Board: RP's board of directors are considered experienced (5.9 years average tenure).

RepliCel Life Sciences Management

Management criteria checks 3/4

Key information

Recent management updates

RepliCel Life Sciences Inc., Annual General Meeting, Dec 30, 2024

RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors

RepliCel Life Sciences Inc., Annual General Meeting, Sep 22, 2023

RepliCel Life Sciences Inc., Annual General Meeting, Feb 28, 2023

RepliCel Life Sciences Inc. Announces Executive Changes

RepliCel Life Sciences Inc., Annual General Meeting, Aug 24, 2022

Recent updates

Third quarter 2024 earnings released: CA$0.004 loss per share (vs CA$0.013 loss in 3Q 2023)

RepliCel Life Sciences Inc., Annual General Meeting, Dec 30, 2024

Third quarter 2023 earnings released: CA$0.013 loss per share (vs CA$0.031 loss in 3Q 2022)

First half 2023 earnings released: CA$0.028 loss per share (vs CA$0.054 loss in 1H 2022)

RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors

RepliCel Life Sciences Inc., Annual General Meeting, Sep 22, 2023

First quarter 2023 earnings released: CA$0.018 loss per share (vs CA$0.023 loss in 1Q 2022)

Full year 2022 earnings released: CA$0.02 loss per share (vs CA$0.13 loss in FY 2021)

RepliCel Life Sciences Inc. announced that it has received CAD 0.01225 million in funding

RepliCel Life Sciences Inc. announced that it has received CAD 0.116419 million in funding

RepliCel Life Sciences Inc. announced that it has received $0.558837 million in funding

RepliCel Life Sciences Inc. announced that it has received CAD 0.841965 million in funding

RepliCel Life Sciences Inc., Annual General Meeting, Feb 28, 2023

Third quarter 2022 earnings released: CA$0.031 loss per share (vs CA$0.026 loss in 3Q 2021)

RepliCel Life Sciences Inc. Announces Executive Changes

RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.8 million in funding

First half 2022 earnings released: CA$0.054 loss per share (vs CA$0.077 loss in 1H 2021)

RepliCel Life Sciences Inc. Receives Test Results Showing That Cells Injected Through the DermaPrecise

RepliCel Life Sciences Inc. Receives and Analyzes All Data and Images from Independent Laboratory Testing of the Dermaprecise Injector Prototype

RepliCel Life Sciences Inc., Annual General Meeting, Aug 24, 2022

RepliCel Life Sciences Inc. announced delayed 20-F filing

RepliCel Life Sciences Inc. announced that it has received CAD 0.99892 million in funding from MainPointe Pharmaceuticals, LLC

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

First half 2021 earnings released: CA$0.077 loss per share (vs CA$0.026 loss in 1H 2020)

RepliCel Life Sciences Inc. announced that it has received $0.16152 million in funding

RepliCel Life Sciences Inc. announced that it has received $0.111574 million in funding

Replicel Life Sciences Inc. Receiveds the First Units of Its Dermal Injector and Is Nearing Completion

Replicel Life Sciences Inc. Announces Record Year in Patents Granted

RepliCel Life Sciences Inc. announced delayed 20-F filing

Full year 2020 earnings released: CA$0.059 loss per share (vs CA$0.13 loss in FY 2019)

RepliCel Life Sciences Inc. announced that it has received CAD 0.492091 million in funding

New 90-day high: CA$0.33

RepliCel Life Sciences Inc. announced that it expects to receive CAD 2.7 million in funding from MainPointe Pharmaceuticals, LLC

New 90-day high: CA$0.24

First half earnings released

RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.155645 million in funding

RepliCel Life Sciences Inc. announced that it expects to receive CAD 4 million in funding

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age